Guidance

Adding 18F labelled radiopharmaceuticals to a diagnostic ARSAC certificate

How to apply to add 18F labelled radiopharmaceuticals used in brain amyloid imaging to your diagnostic ARSAC certificate.

From:
Administration of Radioactive Substances Advisory Committee
Published
1 December 2014

This guidance was withdrawn on

ARSAC certification was replaced by the licencing of employers and practitioners in February 2018.

Information on requirements for licences is available at ARSAC notes for guidance.

There are currently 2 licensed amyloid imaging radiopharmaceuticals available in the UK:

  • 18F-Florbetapir
  • 18F-Florbetaben

Additions applications

To add either of these radiopharmaceuticals to your diagnostic ARSAC certificate, you should submit an additions application and include the following information:

  • confirmation that you work in an institution with recognised dementia experts within a network memory clinic or equivalent
  • the specific intended clinical use
  • confirmation of your participation in or feedback from the relevant MDT and referring dementia experts
  • availability of adequate back-up services, such as second read from an established centre or network

Training requirements

You must also be able to demonstrate that you have met the following training requirements.

Theoretical:

  • knowledge, experience and ARSAC certification for 18F-FDG imaging for differential diagnosis of dementia (9a21v)
  • fundamental aspects of PET/CT imaging
  • specific understanding of brain amyloid imaging in dementia, following attendance at a Reader Training programme or equivalent

Practical:

  • practical experience / image interpretation
  • mentored review of 50 cases (including library cases)
  • previous research experience with brain amyloid imaging would be an advantage

Clinical audit

ARSAC encourages participation in clinical audit of the impact of brain amyloid imaging on patient management.

Published 1 December 2014
Contents

Related content